https://www.selleckchem.com/pr....oducts/pmsf-phenylme
08, 95% CI = 0.92-1.27, = 76.5%, n = 9), cancer-specific mortality (HR = 1.22, 95% CI = 0.89-1.67, = 88.1%, n=3), and progression-free survival (HR = 0.88, 95% CI = 0.75-1.05, = 0, n = 4). No evidence of publication bias was observed in current analysis. In our subgroup analyses, the majority of results were consistent with the main findings. However, several positive correlations were detected in studies with ≥800 cases (HR = 1.20, 95% CI = 1.05-1.37), no immortal time bias (HR = 1.28, 95% CI = 1.10-1.49), an
Like
Comment
Share
